X4 Pharmaceuticals Inc at B Riley Oncology Conference (Virtual) Transcript
Good afternoon. This is Mayank Mamtani. Thanks all for joining us for day two of B. Riley Virtual Oncology Investor Conference. Our next fireside chat is with X4 Pharmaceuticals. I'm pleased to have with me, Paula Ragan, our CEO and President.
Paula, we appreciate you being part of the conference. Maybe to kick us off, it would be -- would love to hear sort of a little bit of state of the union on how to think about X4 in 2022 after a very eventful couple of years and obviously a very pivotal year, this year, with your Phase 3 readout and also expansion of your lead program into different indications.
Thank you so much, Mayank. Appreciate it, and I appreciate the B. Riley team for having us today.
So as you kind of opened up, X4 has an amazing transformative year ahead for us as we think about building the two key pillars of our business.
The first pillar is around primary immunodeficiencies, where we have an ongoing Phase 3
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
